Barbell Medicine Podcast cover image

Episode #222: The Science of Losing Fat vs. Muscle

Barbell Medicine Podcast

00:00

Terzepatide and Weight Loss

The Cermont One trial was done for 72 weeks. There seems to be this dose-dependent relationship between terzepatide and weight loss. Liraglutide is a GLP1 agonist, so a different type of medication but the same family. And they added exercise to the deal to see like, hey, can we prevent lean mass losses?

Play episode from 01:07:01
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app